Vir BiotechnologyVIR
VIR
About: Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Employees: 408
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
141% more call options, than puts
Call options by funds: $9.81M | Put options by funds: $4.07M
45% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 29
6% more funds holding
Funds holding: 196 [Q3] → 207 (+11) [Q4]
3% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 68
0.36% more ownership
Funds ownership: 64.11% [Q3] → 64.47% (+0.36%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
1% less capital invested
Capital invested by funds: $656M [Q3] → $652M (-$4.23M) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$19
245%
upside
Avg. target
$45
723%
upside
High target
$110
1,900%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Goldman Sachs Paul Choi 53% 1-year accuracy 8 / 15 met price target | 282%upside $21 | Buy Maintained | 17 Apr 2025 |
Barclays Gena Wang 7% 1-year accuracy 2 / 28 met price target | 464%upside $31 | Overweight Maintained | 28 Feb 2025 |
HC Wainwright & Co. Patrick Trucchio 15% 1-year accuracy 28 / 186 met price target | 1,900%upside $110 | Buy Reiterated | 28 Feb 2025 |
Needham Joseph Stringer 23% 1-year accuracy 27 / 117 met price target | 245%upside $19 | Buy Reiterated | 27 Feb 2025 |
Financial journalist opinion
Neutral
PRNewsWire
4 weeks ago
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results
Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure Data from Multiple Ongoing Late-Stage Studies Reinforce Brii Bio's HBV Functional Cure Strategy of Optimized Combination Regimens to Target Patient Populations 4 Abstracts Including 2 Oral Presentations with Data from the Ongoing Phase 2 ENSURE Study at the Upcoming APASL (March 26-30) Strong Cash Reserves of US$335.7 Million to Propel Operations into 2028 Actively Seeking Partnership Opportunities for Non-HBV Programs Conference Call (English Session) Scheduled for March 31 at 8:30 PM HKT / 8:30 AM ET DURHAM, N.C. and BEIJING, China , March 21, 2025 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health across diseases with high unmet medical needs provided a corporate update today and reported its financial results for the year ended December 31, 2024.
Neutral
Business Wire
1 month ago
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is designed to evaluate the efficacy and safety of tobevibart in combination with elebsiran in people living with chronic hepatitis delta (CHD). ECLIPSE 1, the first trial of the program to be initiated, and ECLIPSE 2 are Phase 3 trials designed to provide the registrational data needed for sub.
Neutral
Seeking Alpha
1 month ago
Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Mark Eisner - Executive Vice President & Chief Medical Officer Jason O'Byrne - Executive Vice President & Chief Financial Officer Mika Derynck - Executive Vice President of Therapeutic Head Oncology Conference Call Participants Hang Hu - Barclays Paul Choi - Goldman Sachs Phil Nadeau - TD Cowen Alec Stranahan - Bank of America Joseph Stringer - Needham Patrick Trucchio - H.C. Wainwright & Co. Operator Hello.
Negative
Zacks Investment Research
1 month ago
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.86 per share a year ago.
Neutral
Business Wire
1 month ago
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2024. “2024 was a year of transformation for Vir Biotechnology as we successfully defined and executed on our renewed strategic direction, focusing our resources on our most promising programs in infectious diseases and oncology,” said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Bio.
Neutral
Business Wire
1 month ago
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the executive team are scheduled to participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 at 8:50 a.m. PT / 11:50 a.m. ET in Boston, Massachusetts. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days. About Vir Biotech.
Neutral
Business Wire
2 months ago
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2024, on February 26, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on February 26, 2025. The corporate update and financial results will be provided via a press release after market close and will be accessible on the News page in the Investors s.
Positive
Seeking Alpha
3 months ago
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.
Positive
Benzinga
3 months ago
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
On Wednesday, Vir Biotechnology, Inc. VIR presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid tumors, and VIR-5500, which targets PSMA in metastatic castration-resistant prostate cancer (mCRPC).
Positive
Zacks Investment Research
3 months ago
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
Vir Biotechnology posts encouraging initial data from phase I studies evaluating VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors.
Charts implemented using Lightweight Charts™